ATE336988T1 - Venlafaxine hydrochloridformulierungen mit verzögerter freisetzung - Google Patents

Venlafaxine hydrochloridformulierungen mit verzögerter freisetzung

Info

Publication number
ATE336988T1
ATE336988T1 AT03386019T AT03386019T ATE336988T1 AT E336988 T1 ATE336988 T1 AT E336988T1 AT 03386019 T AT03386019 T AT 03386019T AT 03386019 T AT03386019 T AT 03386019T AT E336988 T1 ATE336988 T1 AT E336988T1
Authority
AT
Austria
Prior art keywords
drug
sustained release
formulation
functional
drug substance
Prior art date
Application number
AT03386019T
Other languages
English (en)
Inventor
Evangelos Karavas
Konstantinos Lioumis
Stavros Politis
Original Assignee
Pharmathen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen Sa filed Critical Pharmathen Sa
Application granted granted Critical
Publication of ATE336988T1 publication Critical patent/ATE336988T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
AT03386019T 2003-07-30 2003-07-30 Venlafaxine hydrochloridformulierungen mit verzögerter freisetzung ATE336988T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03386019A EP1502587B1 (de) 2003-07-30 2003-07-30 Venlafaxine Hydrochloridformulierungen mit verzögerter Freisetzung

Publications (1)

Publication Number Publication Date
ATE336988T1 true ATE336988T1 (de) 2006-09-15

Family

ID=33522496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03386019T ATE336988T1 (de) 2003-07-30 2003-07-30 Venlafaxine hydrochloridformulierungen mit verzögerter freisetzung

Country Status (15)

Country Link
US (2) US20060182797A1 (de)
EP (1) EP1502587B1 (de)
AT (1) ATE336988T1 (de)
AU (1) AU2004258732B2 (de)
BR (1) BRPI0412354A (de)
CA (1) CA2529393C (de)
CY (1) CY1107576T1 (de)
DE (1) DE60307819T2 (de)
DK (1) DK1502587T3 (de)
ES (1) ES2271514T3 (de)
PL (1) PL207998B1 (de)
PT (1) PT1502587E (de)
SI (1) SI1502587T1 (de)
WO (1) WO2005009414A1 (de)
ZA (1) ZA200600790B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
CA2507685A1 (en) * 2002-11-28 2004-06-10 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
PL1711169T3 (pl) * 2004-02-04 2007-10-31 Alembic Ltd Powlekane tabletki chlorowodorku wenlafaksyny o wydłużonym czasie uwalniania
WO2006136927A1 (en) * 2005-06-22 2006-12-28 Glenmark Pharmaceuticals Limited Extended release formulations comprising venlafaxine
EP1898886B1 (de) * 2005-07-01 2019-09-04 Rubicon Research Pvt Ltd. Neuartige dosierungsform mit verzögerter freisetzung
US7427414B2 (en) * 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
WO2007102169A1 (en) * 2006-03-08 2007-09-13 Jubilant Organosys Limited Extended release pharmaceutical formulation of venlafaxine and method of manufacturing the same
WO2007112574A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Extended release composition of venlafaxine
PL2010158T3 (pl) 2006-04-26 2016-09-30 Formulacje o kontrolowanym uwalnianiu zawierające niepowlekaną odrębną jednostkę(-i) i macierz o przedłużonym uwalnianiu
WO2008140461A1 (en) * 2007-05-16 2008-11-20 Fmc Corporation Solid form
JP2011500605A (ja) * 2007-10-16 2011-01-06 アルファファーム ピーティーワイ リミテッド 制御放出医薬配合物
EP2403487A2 (de) * 2009-03-04 2012-01-11 Fdc Limited Orale darreichungsformen mit verzögerter freisetzung für wasserlösliche arzneimittel
US20130004563A1 (en) * 2011-06-07 2013-01-03 Shah Syed Multiparticulate s-adenosylmethionine compositions and related methods
CN103948557A (zh) * 2014-04-08 2014-07-30 闻晓光 一种新型控释片

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
CA2698347A1 (en) 1999-05-20 2000-11-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
BR0100334A (pt) 2001-01-17 2002-09-24 Diffucap Chemobras Quimica E F Processo para a preparação de composições de liberação programada contendo venlafaxina e o produto resultante
NZ528957A (en) * 2001-04-18 2005-05-27 Nostrum Pharmaceuticals Inc A novel coating for a sustained release pharmaceutical composition
WO2003013480A1 (en) * 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
WO2003082805A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Low water-soluble venlafaxine salts

Also Published As

Publication number Publication date
DE60307819D1 (de) 2006-10-05
AU2004258732A1 (en) 2005-02-03
PT1502587E (pt) 2007-01-31
ES2271514T3 (es) 2007-04-16
DK1502587T3 (da) 2007-01-02
EP1502587A1 (de) 2005-02-02
PL379465A1 (pl) 2006-09-18
CA2529393A1 (en) 2005-02-03
CA2529393C (en) 2010-08-17
SI1502587T1 (sl) 2007-02-28
EP1502587B1 (de) 2006-08-23
AU2004258732B2 (en) 2009-06-11
BRPI0412354A (pt) 2006-09-05
CY1107576T1 (el) 2013-03-13
US20060182797A1 (en) 2006-08-17
DE60307819T2 (de) 2007-10-04
PL207998B1 (pl) 2011-02-28
US20110171297A1 (en) 2011-07-14
ZA200600790B (en) 2007-04-25
WO2005009414A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
CY1107576T1 (el) Ταχεια αποδεσμευση των υδατοδιαλυτων φαρμακευτικων ουσιων
AP1748A (en) Chronotherapeutic dosage forms.
WO2004026262A3 (en) Abuse-resistant pharmaceutical compositions
HRP20040323C1 (hr) Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli s produljenim oslobađanjem djelotvone supstance
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
WO2002028376A3 (en) Chrono delivery formulations and method of use thereof
WO2004012699A3 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
CA2417686A1 (en) Manufacture of oral dosage forms delivering both immediate release and sustained release drugs
MXPA02012792A (es) Composicion y forma de de dosificacion para liberacion gastrica retardada de alendronato y/u otros bis-fosfonatos.
CA2251886A1 (en) An oral pharmaceutical formulation containing ibandronate
UY24288A1 (es) Procedimiento para la preparación de una composición de liberación retardada de paroxetina
NZ594618A (en) Transdermal pharmaceutical preparations
WO2005027843A3 (en) Chronotherapeutic dosage forms
EP2397122A3 (de) Formulierungen aus Neramexan-Dosierformen
ATE549015T1 (de) Pharmazeutische wirkstoffhaltige formulierung mit überzug
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
CA2453263A1 (en) Pharmaceutical compositions containing terbinafine and use thereof
ES2185452A1 (es) Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
IL154731A0 (en) Ion-strength independent sustained release pharmaceutical formulation
WO2001013898A3 (en) Pharmaceutical formulations with different release times
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
DE69827466D1 (de) Geschmacksneutrale pharmazeutische zusammensetzungen
CA2516327A1 (en) Therapeutic system comprising amoxicillin and clavulanic acid
WO2004073592A3 (en) Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1502587

Country of ref document: EP